Aster Launches OURA/USD1 Pre-IPO Perpetual Futures Ahead of Nasdaq Listing
Decentralized exchange Aster has launched a perpetual futures contract tied to Oura Health’s upcoming IPO, providing crypto traders with a means to speculate on the Finnish smart ring maker’s public market debut with leverage of up to 20 times. The OURA/USD1 Pre-IPO Perpetual became available on September 23, just two days after Oura commenced its IPO roadshow.
Oura is aiming for a Nasdaq listing under the ticker ‘OURA,’ with plans to offer 50 million shares priced between $40 and $44. This pricing strategy sets the company’s fundraising target at approximately $2.2 billion, resulting in a fully diluted valuation estimated between $14.1 billion and $15.6 billion.
For Your Trading Desk
Sponsor Spike Success.
The contract functions as a synthetic perpetual future, meaning it tracks the market-implied price per share of Oura without granting any actual equity ownership. Traders are essentially betting on the stock's future performance rather than acquiring a stake in the company itself.
All settlements for this contract occur in USD1, a dollar-pegged stablecoin developed by World Liberty Financial. Aster has been strategically expanding its product offerings to utilize USD1 as the exclusive settlement asset for its real-world asset and select equity perpetual contracts.
The OURA listing is also part of Aster’s USD1 RWA Boost rewards campaign, which runs until December 31, 2026. This initiative aims to encourage liquidity provision across these newer contract types, supported by a fund of nearly $28 million allocated for earlier listings in the same category.
Aster has been enhancing this segment of its platform throughout 2026, with pre-IPO perpetuals already available for SpaceX (under the ticker SPCX) and OpenAI.
Oura Health's IPO Roadshow and Valuation Insights
Oura Health filed its S-1 Registration Statement for its Nasdaq listing and began its roadshow on September 21. With the proposed price range of $40 to $44 per share, the IPO would value Oura at between $14.1 billion and $15.6 billion on a fully diluted basis. Notably, around 73% of the proceeds are expected to benefit existing shareholders rather than contribute to the company’s treasury, indicating that early investors and insiders are looking to monetize their positions.
Aster’s pre-IPO perpetual contracts provide crypto-native traders access to price movements that would typically be restricted by accredited investor requirements, brokerage accounts, and IPO allocation lotteries. These synthetic instruments do not confer any claim on actual equity, meaning there are no dividends, voting rights, or participation in corporate governance. The 20x leverage ceiling implies that a 5% adverse movement against a fully leveraged position could result in the total loss of the stake.
The use of USD1 as the settlement layer is significant beyond this particular listing. World Liberty Financial’s stablecoin is becoming a foundational element of Aster’s RWA strategy, and these pre-IPO products exemplify stablecoin adoption, with every transaction processed through USD1 rather than traditional banking systems.
Market Sentiment and Regulatory Concerns Surrounding Aster's Perpetual Contracts
As the IPO roadshow progresses, the perpetual contract’s price on Aster will reflect real-time sentiment from the crypto market. If the perpetual contract trades consistently above the $40 to $44 range, it indicates that crypto traders are more optimistic than the underwriters’ pricing. Conversely, if it trades below this range, it suggests a bearish sentiment.
The potential for regulatory scrutiny regarding synthetic pre-IPO instruments on decentralized exchanges is a concern. These products effectively enable unregistered, leveraged speculation on securities that have not yet been listed on regulated exchanges.




